拓僖联合栓塞治疗中晚期原发性肝癌57例疗效分析  

HCPT combined embolization in the treatment of advanced primary hepatic carcinoma:a report of 57 cases

作　　者：董琨[1] 冯永毅 陈洪学 

机构地区：[1]解放军第三零二医院感染内科,北京100039 [2]黑龙江双鸭山矿业集团第二医院

出　　处：《中国肿瘤临床与康复》2005年第4期362-364,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的观察拓僖(HCPT,羟基喜树碱冻干粉针)为主的灌注化疗联合碘油栓塞治疗原发性中晚期原发性肝癌(PHC)的疗效和毒副作用。方法采用HCPT加氟尿嘧啶(5-Fu)、吡柔比星(THP)肝动脉灌注联合碘油(LP)肝动脉栓塞的化疗栓塞治疗方案,治疗中晚期原发性肝癌患者57例。结果57例患者共接受化疗栓塞112次。部分缓解(PR)17例,稳定(NC)26例,进展(PD)14例,生存率6个月为81.8%,1年为54.5%,2年为22.7%。除进展病例外,患者临床症状(食欲减退、乏力、肝区疼痛等)均有不同程度改善。不良反应主要表现为发热、肝区疼痛、肝功波动、消化道症状和轻度骨髓抑制。在严重肝硬化基础上并发肝癌的患者肝动脉化疗栓塞后恢复缓慢。结论以HCPT为主灌注化疗联合肝动脉栓塞方案治疗中晚期肝癌,有可能延长患者生存期,提高生存质量,副作用小,但对于合并肝硬化的患者需要同时加强保肝治疗。Objective To observe the curative efficacy and the side effects of chemotherapy with HCPT and hepatic arterial embohzation in the treatment of advanced primary hepatic carcinoma. Methods Fifty-seven patients with advanced primary hepatic carcinoma were treated with HCPT ＋ 5-Fu ＋ THP infusion combined with LP arterial embolization. Results Fifty-seven cases were treated for 112 times. 17 cases achieved PR,26 cases achieved NC, 14 eases achieved PD. The 6-month, 1-year, and 2-year survival rate were 81.8%, 54.5% and 22.7% respectively. The clinical symptoms were improved obviously except for the PD cases . The main side effects were fever, ache, liver function damage, nauseous and marrow restrain. The patients with severe cirrhosis proved recovered slowly. Conclusion HCPT ＋ 5-Fu ＋ THP infusion compared with LP arterial embolization treatment of advanced hepatic carcinoma could prolong the survival period and improve the quality of life, but the patients with cirrhosis needed more time to recover.

关 键 词：肝肿瘤 化学治疗 羟基喜树碱 

分 类 号：R735.7[医药卫生—肿瘤] R730.53[医药卫生—临床医学]